Trimodal Therapy Promising for Recurrent High-Grade T1 Bladder Cancer
Trimodal therapy shows potential as an alternative to radical cystectomy for recurrent high-grade T1 bladder cancer, with 88% of patients avoiding cystectomy at 3 years post-treatment. The therapy, involving radiation with radiosensitizing chemotherapy following repeated transurethral resection, reported overall survival rates of 69% at 3 years and 56% at 5 years, with 12% and 19% distant metastasis rates, respectively. Despite limitations in cohort size and participant heterogeneity, the study suggests this approach could be considered in place of cystectomy.
Reference News
Trimodal therapy shows potential as an alternative to radical cystectomy for recurrent high-grade T1 bladder cancer, with 88% of patients avoiding cystectomy at 3 years post-treatment. The therapy, involving radiation with radiosensitizing chemotherapy following repeated transurethral resection, reported overall survival rates of 69% at 3 years and 56% at 5 years, with 12% and 19% distant metastasis rates, respectively. Despite limitations in cohort size and participant heterogeneity, the study suggests this approach could be considered in place of cystectomy.